JMPWA
SUPN icon

JP Morgan Private Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$354K Sell
12,830
-164
-1% -$4.99K ﹤0.01% 1395
2023
Q2 		$391K Sell
12,994
-1,949
-13% -$68.2K ﹤0.01% 1127
2023
Q1 		$541K Sell
14,943
-934
-6% -$35.9K ﹤0.01% 1442
2022
Q4 		$566K Sell
15,877
-1,643
-9% -$57.1K ﹤0.01% 1419
2022
Q3 		$593K Sell
17,520
-1,309
-7% -$42.6K ﹤0.01% 1382
2022
Q2 		$545K Sell
18,829
-410
-2% -$11.7K ﹤0.01% 1426
2022
Q1 		$622K Sell
19,239
-3,356
-15% -$103K ﹤0.01% 1439
2021
Q4 		$659K Buy
22,595
+1,262
+6% +$38.3K ﹤0.01% 1440
2021
Q3 		$569K Buy
21,333
+284
+1% +$7.62K ﹤0.01% 1452
2021
Q2 		$648K Buy
21,049
+42
+0.2% +$1.29K ﹤0.01% 1386
2021
Q1 		$550K Buy
21,007
+2,248
+12% +$62.9K ﹤0.01% 1274
2020
Q4 		$472K Sell
18,759
-4,035
-18% -$86.8K ﹤0.01% 1313
2020
Q3 		$475K Buy
22,794
+964
+4% +$21.9K ﹤0.01% 1178
2020
Q2 		$518K Buy
21,830
+3,997
+22% +$88.3K ﹤0.01% 1074
2020
Q1 		$321K Buy
17,833
+3,560
+25% +$74.8K ﹤0.01% 1105
2019
Q4 		$339K Sell
14,273
-803
-5% -$19.5K ﹤0.01% 1185
2019
Q3 		$414K Buy
15,076
+5,178
+52% +$153K ﹤0.01% 1062
2019
Q2 		$328K Sell
9,898
-281
-3% -$9.63K ﹤0.01% 1117
2019
Q1 		$357K Sell
10,179
-36
-0.4% -$1.34K ﹤0.01% 1143
2018
Q4 		$339K Sell
10,215
-489
-5% -$21K ﹤0.01% 1108
2018
Q3 		$539K Sell
10,704
-1,868
-15% -$92.2K ﹤0.01% 1042
2018
Q2 		$753K Buy
12,572
+1,179
+10% +$61.1K ﹤0.01% 869
2018
Q1 		$522K Buy
11,393
+649
+6% +$27.1K ﹤0.01% 852
2017
Q4 		$428K Sell
10,744
-189
-2% -$7.47K ﹤0.01% 924
2017
Q3 		$437K Buy
10,933
+1,208
+12% +$52.3K ﹤0.01% 899
2017
Q2 		$419K Buy
9,725
+965
+11% +$34.3K ﹤0.01% 890
2017
Q1 		$274K Buy
+8,760
New +$235K ﹤0.01% 1104
2016
Q1 		– Sell
-12,080
Closed -$162K – 1295
2015
Q4 		$162K Buy
+12,080
New +$187K ﹤0.01% 1047

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Private Wealth Advisors's SUPN Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 1.3% in Q3 2023, selling an estimated $4.99K and leaving 12,830 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

JP Morgan Private Wealth Advisors first reported a position in SUPN in Q4 2015 and has held it in 28 quarters since. The position peaked at $753K in Q2 2018. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 12,830 shares of Supernus Pharmaceuticals worth $354K as of Q3 2023.
  • JP Morgan Private Wealth Advisors sold 164 Supernus Pharmaceuticals shares in Q3 2023, an estimated $4.99K.
  • Supernus Pharmaceuticals made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1395 holding.
  • JP Morgan Private Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • JP Morgan Private Wealth Advisors's Supernus Pharmaceuticals position peaked at $753K in Q2 2018.
  • 238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.